Genetic polymorphism ofCYP1A2but not total or free teriflunomide concentrations is associated with leflunomide cessation in rheumatoid arthritis-Reference-Cited by-同舟云学术

Genetic polymorphism ofCYP1A2but not total or free teriflunomide concentrations is associated with leflunomide cessation in rheumatoid arthritis

Published:2015-10-28 Issue:1 Volume:81 Page:113-123
ISSN:0306-5251
Container-title:British Journal of Clinical Pharmacology
language:en
Short-container-title:Br J Clin Pharmacol

Author:

Hopkins Ashley M.¹²,Wiese Michael D.²,Proudman Susanna M.³⁴,O'Doherty Catherine E.²,Upton Richard N.¹²,Foster David J. R.¹²

Affiliation:

1. Australian Centre for Pharmacometrics, School of Pharmacy and Medical Sciences; University of South Australia; Frome Road, GPO Box 2471 Adelaide South Australia 5000

2. School of Pharmacy and Medical Sciences; University of South Australia, Sansom Institute for Health Research; Frome Road, GPO Box 2471 Adelaide South Australia 5000

3. Department of Rheumatology; Royal Adelaide Hospital; North Terrace Adelaide South Australia 5000

4. Discipline of Medicine; Adelaide University; North Terrace Adelaide South Australia 5000 Australia

Funder

the Australian Centre for Pharmacometrics is an initiative of the Australian Government as part of the National Collaborative Research Infrastructure Strategy

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/bcp.12760/fullpdf

Reference45 articles.

1. Rheumatoid arthritis;Scott;Lancet,2010

2. Current evidence for the management of rheumatoid arthritis with synthetic disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis;Gaujoux-Viala;Ann Rheum Dis,2010

3. 2012 update of the 2008 american college of rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis;Singh;Arthritis Care Res,2012

4. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update;Smolen;Ann Rheum Dis,2014

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Frequency and impact of DHODH, ABCG2 and CYP2C19 SNPs on the therapeutic efficacy, tolerability and toxicity of leflunomide;Pharmacogenomics;2021-12

2. Development and validation of a prognostic model for leflunomide discontinuation with abnormal blood tests during long-term treatment: cohort study using data from the Clinical Practice Research Datalink Gold and Aurum;Rheumatology;2021-10-27

3. Leflunomide: modern look at safety problem (literature review);Medical alphabet;2021-08-19

4. Precision Medicine With Leflunomide: Consideration of the DHODH Haplotype and Plasma Teriflunomide Concentration and Modification of Outcomes in Patients With Rheumatoid Arthritis;Arthritis Care & Research;2021-06-28

5. Biomarkers to Personalize the Treatment of Rheumatoid Arthritis: Focus on Autoantibodies and Pharmacogenetics;Biomolecules;2020-12-14